A feasibility randomised controlled trial assessing the use of platelet transfusions versus modified dose anticoagulation in patients with thrombocytopaenia and cancer-associated thrombosis receiving anticoagulation (START UK)

niversity College London0 个研究点目标入组 20 人开始时间: 2024年7月8日最近更新: 2024年9月9日

适应症

试验速览

暂无简介。

•1. Adult participants (age =18 years) with active malignancy (malignancy diagnosed or treated within the previous 6 months, or progressive/relapsed)
•2. Imaging confirmed pulmonary embolism, deep vein thrombosis (proximal or distal, including central venous catheter-related DVT), or unusual site VTE (either symptomatic or incidentally diagnosed) within the last 14 days for which anticoagulation is planned (including VTE in the deep vein system that progressed from a prior superficial vein thrombosis for which anticoagulation is to be started)
•3. Platelet count <50 x 10e9/L from cancer therapy or malignancy itself
•4. Able to provide written informed consent

•1. Receipt of anticoagulant for index VTE with platelet count <50 x10 9/L for >72 hours
•2. Superficial vein thrombosis only
•3. Tumour thrombus
•4. Life expectancy <1 month (as judged by the treating physicians)
•5. Creatinine clearance < 30 ml/min
•6. Contraindication to LMWH such as a history of heparin induced thrombocytopaenia
•7. Thrombocytopaenia from other causes, such as thrombotic microangiopathy, immune thrombocytopaenia, disseminated intravascular coagulation
•8. Previously documented history of refractoriness to platelet transfusion secondary to HLA antibodies
•9. Refusal of blood products
•10. Anticoagulation at any dose is deemed unsafe (i.e. recent, active bleeding or inherited bleeding disorders)

发起方

niversity College London